Animal models of Alzheimer disease.

Significant insights into the function of genes associated with Alzheimer disease and related dementias have occurred through studying genetically modified animals. Although none of the existing models fully reproduces the complete spectrum of this insidious human disease, critical aspects of Alzheimer pathology and disease processes can be experimentally recapitulated. Genetically modified animal models have helped advance our understanding of the underlying mechanisms of disease and have proven to be invaluable in the preclinical evaluation of potential therapeutic interventions. Continuing refinement and evolution to yield the next generation of animal models will facilitate successes in producing greater translational concordance between preclinical studies and human clinical trials and eventually lead to the introduction of novel therapies into clinical practice.

[1]  M. Staufenbiel,et al.  Extracellular amyloid formation and associated pathology in neural grafts , 2003, Nature Neuroscience.

[2]  D. Price,et al.  Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice , 2008, Proceedings of the National Academy of Sciences.

[3]  J. Hardy,et al.  Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice , 2005, Neuron.

[4]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[5]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[6]  Kim N. Green,et al.  Intracellular amyloid-β in Alzheimer's disease , 2007, Nature Reviews Neuroscience.

[7]  K. Davis,et al.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.

[8]  D. Price,et al.  Reduced BACE1 Activity Enhances Clearance of Myelin Debris and Regeneration of Axons in the Injured Peripheral Nervous System , 2011, The Journal of Neuroscience.

[9]  D. Wilcock,et al.  Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice , 2001, Neurobiology of Aging.

[10]  S. Oddo,et al.  The ubiquitin-proteasome system in Alzheimer's disease , 2008, Journal of cellular and molecular medicine.

[11]  F. LaFerla,et al.  Intracellular amyloid-beta in Alzheimer's disease. , 2007, Nature reviews. Neuroscience.

[12]  C. Holmes,et al.  Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis , 2010, Acta Neuropathologica.

[13]  A. Palmeri,et al.  Phosphodiesterase 5 Inhibition Improves Synaptic Function, Memory, and Amyloid-β Load in an Alzheimer's Disease Mouse Model , 2009, The Journal of Neuroscience.

[14]  T. Iwatsubo,et al.  A Noncompetitive BACE1 Inhibitor TAK-070 Ameliorates Aβ Pathology and Behavioral Deficits in a Mouse Model of Alzheimer's Disease , 2010, The Journal of Neuroscience.

[15]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[16]  D. Sirinathsinghji,et al.  Mice Deficient for the Amyloid Precursor Protein Gene , 1996, Annals of the New York Academy of Sciences.

[17]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[18]  D. Westaway,et al.  Lysosomal Proteolysis and Autophagy Require Presenilin 1 and Are Disrupted by Alzheimer-Related PS1 Mutations , 2010, Cell.

[19]  G. Münch,et al.  The molecular basis of the prevention of Alzheimer’s disease through healthy nutrition , 2007, Experimental Gerontology.

[20]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[21]  David C. Lee,et al.  TACE/ADAM17 Processing of EGFR Ligands Indicates a Role as a Physiological Convertase , 2003, Annals of the New York Academy of Sciences.

[22]  A. Marighetto,et al.  Comparative effects of the α7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice , 2008, Psychopharmacology.

[23]  F. LaFerla,et al.  Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.

[24]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[25]  F. LaFerla,et al.  Pathways by which Abeta facilitates tau pathology. , 2006, Current Alzheimer research.

[26]  C. Sanders,et al.  Substrate specificity of γ-secretase and other intramembrane proteases , 2008, Cellular and Molecular Life Sciences.

[27]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[28]  H. Cai,et al.  BACE1, a Major Determinant of Selective Vulnerability of the Brain to Amyloid-β Amyloidogenesis, is Essential for Cognitive, Emotional, and Synaptic Functions , 2005, The Journal of Neuroscience.

[29]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[30]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[31]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[32]  T. Montine,et al.  Quantitation and Mapping of Cerebral Detergent‐Insoluble Proteins in the Elderly , 2009, Brain pathology.

[33]  J. Trojanowski,et al.  The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging , 1999, Experimental Neurology.

[34]  D. Westaway,et al.  Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.

[35]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.

[36]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[37]  R. Kayed,et al.  Soluble Aβ oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain , 2005, Brain Research.

[38]  S. Tonegawa,et al.  Skeletal and CNS Defects in Presenilin-1-Deficient Mice , 1997, Cell.

[39]  K. Blennow,et al.  PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. , 2010, Journal of Alzheimer's disease : JAD.

[40]  R. Schliebs,et al.  Induction of cytokines in glial cells surrounding cortical β-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology , 2000, International Journal of Developmental Neuroscience.

[41]  A. Smith,et al.  Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. , 1995, Dementia.

[42]  T. Bayer,et al.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. , 2004, The American journal of pathology.

[43]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[44]  C. Glabe,et al.  Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction , 2009, Neurobiology of Disease.

[45]  B. Trapp,et al.  Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[47]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[48]  P. Jeffrey,et al.  Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo , 2007 .

[49]  D. Selkoe,et al.  Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.

[50]  T. Poulos,et al.  The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation☆ , 1999, Neurobiology of Aging.

[51]  Alison R. Gregro,et al.  First Demonstration of Cerebrospinal Fluid and Plasma Aβ Lowering with Oral Administration of a β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates , 2009, Journal of Pharmacology and Experimental Therapeutics.

[52]  M. Ball,et al.  Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.

[53]  P. Saftig,et al.  Klotho is a substrate for α‐, β‐ and γ‐secretase , 2009 .

[54]  P. Wong,et al.  Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.

[55]  Rudi D'Hooge,et al.  Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient Mice* , 2005, Journal of Biological Chemistry.

[56]  Jürgen Götz,et al.  A Decade of Tau Transgenic Animal Models and Beyond , 2007, Brain pathology.

[57]  M. Ohno,et al.  BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.

[58]  Nastaran Gharkholonarehe,et al.  Progression of Amyloid Pathology to Alzheimer's Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2 , 2008, The Journal of Neuroscience.

[59]  J. Troncoso,et al.  Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. , 2001, Archives of pathology & laboratory medicine.

[60]  N. Schor What the halted phase III γ‐secretase inhibitor trial may (or may not) be telling us , 2011, Annals of neurology.

[61]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[62]  P. Saftig,et al.  Control of Peripheral Nerve Myelination by the ß-Secretase BACE1 , 2006, Science.

[63]  B. de Strooper,et al.  β Subunits of Voltage-gated Sodium Channels Are Novel Substrates of β-Site Amyloid Precursor Protein-cleaving Enzyme (BACE1) and γ-Secretase* , 2005, Journal of Biological Chemistry.

[64]  Kim N. Green,et al.  Linking Calcium to Aβ and Alzheimer's Disease , 2008, Neuron.

[65]  D. Walsh,et al.  Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.

[66]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[67]  Anne W. Schmidt,et al.  Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. , 2009, Journal of medicinal chemistry.

[68]  Michael A. Briggs,et al.  GSK189254, a Novel H3 Receptor Antagonist That Binds to Histamine H3 Receptors in Alzheimer's Disease Brain and Improves Cognitive Performance in Preclinical Models , 2007, Journal of Pharmacology and Experimental Therapeutics.

[69]  H. Vanderstichele,et al.  Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[70]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[71]  N. Hirokawa,et al.  Defects in Axonal Elongation and Neuronal Migration in Mice with Disrupted tau and map1b Genes , 2000, The Journal of cell biology.

[72]  Huaxi Xu,et al.  Presenilin/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression , 2007, Proceedings of the National Academy of Sciences.

[73]  Yongzhou Hu,et al.  Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease. , 2009, Current medicinal chemistry.

[74]  F. LaFerla,et al.  Neural Stem Cells Improve Memory in an Inducible Mouse Model of Neuronal Loss , 2007, The Journal of Neuroscience.

[75]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[76]  D. Morgan Immunotherapy for Alzheimer’s disease , 2011, Journal of internal medicine.

[77]  F. LaFerla,et al.  Presenilin Is Necessary for Efficient Proteolysis through the Autophagy–Lysosome System in a γ-Secretase-Independent Manner , 2011, The Journal of Neuroscience.

[78]  Arun K. Ghosh,et al.  In vivo inhibition of Aβ production by memapsin 2 (β‐secretase) inhibitors , 2004, Journal of neurochemistry.

[79]  Doo Yeon Kim,et al.  Reduced Sodium Channel Nav1.1 Levels in BACE1-null Mice* , 2010, The Journal of Biological Chemistry.

[80]  M. Staufenbiel,et al.  Macrocyclic BACE-1 inhibitors acutely reduce Abeta in brain after po application. , 2010, Bioorganic & medicinal chemistry letters.

[81]  K. Ashe,et al.  Plaque-associated alpha-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. , 2000, Brain research.

[82]  B. de Strooper,et al.  The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. , 2002, Human molecular genetics.

[83]  M. Findeis The role of amyloid β peptide 42 in Alzheimer's disease , 2007 .

[84]  C. Masters,et al.  Rapid Restoration of Cognition in Alzheimer's Transgenic Mice with 8-Hydroxy Quinoline Analogs Is Associated with Decreased Interstitial Aβ , 2008, Neuron.

[85]  D. Selkoe,et al.  Intraneuronal Abeta42 accumulation in Down syndrome brain. , 2002, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[86]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[87]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.